MedKoo Cat#: 525846 | Name: PD 138312

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD 138312 is a novel broad-spectrum 7-pyrrolidinyl fluoronaphthyridines with a cyclopropyl or a difluorophenyl substitution at the 1 positions, respectively. It has been demonstrated to have excellent in vitro activity against gram-positive organisms. This compound was evaluated for its in vivo potencies against acute systemic infections in mice and in a mouse pneumococcal pneumonia model. Most remarkable was its comparative median protective value against methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. PD 138312 has excellent therapeutic potential against clinically important gram-positive pathogens when the drugs are administered both orally and parenterally.

Chemical Structure

PD 138312
PD 138312
CAS#107334-06-5 (free base)

Theoretical Analysis

MedKoo Cat#: 525846

Name: PD 138312

CAS#: 107334-06-5 (free base)

Chemical Formula: C19H23FN4O3

Exact Mass: 374.1754

Molecular Weight: 374.41

Elemental Analysis: C, 60.95; H, 6.19; F, 5.07; N, 14.96; O, 12.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
153566-55-3 (HCl); 107334-06-5 (free base)
Synonym
PD-138312; PD138312; PD 138312
IUPAC/Chemical Name
7-(3-(2-aminopropan-2-yl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
InChi Key
WZGKUGHHTACDTE-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23FN4O3/c1-19(2,21)10-5-6-23(8-10)17-14(20)7-12-15(25)13(18(26)27)9-24(11-3-4-11)16(12)22-17/h7,9-11H,3-6,8,21H2,1-2H3,(H,26,27)
SMILES Code
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(C(C)(N)C)CC4)=N3)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 374.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shapiro MA, Dever JA, Joannides ET, Sesnie JC, Vanderroest SR. In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1995 Oct;39(10):2183-6. PubMed PMID: 8619563; PubMed Central PMCID: PMC162910. 2: Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney CL. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. PubMed PMID: 8540728; PubMed Central PMCID: PMC162893. 3: Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. PubMed PMID: 8192468; PubMed Central PMCID: PMC284459. 4: Huband MD, Cohen MA, Meservey MA, Roland GE, Yoder SL, Dazer ME, Domagala JM. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1993 Dec;37(12):2563-70. PubMed PMID: 8109918; PubMed Central PMCID: PMC192739. 5: Sánchez-Hernández J, Manzanares MA, Gutiérrez Zufiaurre MN, Muñoz Criado S, Muñoz Bellido JL, García-Rodríguez JA. In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia. Rev Esp Quimioter. 1999 Sep;12(3):234-6. PubMed PMID: 10878514. 6: García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother. 1995 May;39(5):1194-5. PubMed PMID: 7625815; PubMed Central PMCID: PMC162710. 7: Hagen SE, Domagala JM, Gracheck SJ, Sesnie JA, Stier MA, Suto MJ. Synthesis and antibacterial activity of new quinolones containing a 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl] moiety. Gram-positive agents with excellent oral activity and low side-effect potential. J Med Chem. 1994 Mar 18;37(6):733-8. PubMed PMID: 8145222. 8: Cohen MA, Gage JW, Huband MD, Meservey MA, VanderRoest SR, Yoder SL. Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice. J Antimicrob Chemother. 1995 Sep;36(3):551-5. PubMed PMID: 8830021.